Articles Tagged With:
-
IRB Coordinators Can Get a Lot Done in a 30-minute Sit-down
The IRB of Oregon State University has found that short, in-person meetings with researchers can result in greater communication, collaboration, and efficiency.
-
Olympic Athletes, Staff Enrolled in Zika Virus Study
In an ongoing study of 1,000 U.S. athletes, coaches, and staff that recently traveled to Brazil for the Olympic Games, researchers are performing antibody testing to see if any acquired Zika virus.
-
The How and Why of Returning Study Results
Returning a layperson summary of study results to research volunteers is the right thing to do that also could benefit the research community, several human research protection experts say.
-
EU’s Requirements for Returning Trial Results
The EU’s European Clinical Trial Regulation requires clinical trial sponsors to create layperson-friendly content for the summary of results.
-
EU Will Require More Clinical Trial Transparency — Will U.S. Be Next?
The European Union soon will require investigators to give people the kind of transparent, easy-to-access clinical trials information they’ve been conditioned to expect in the age of Google.
-
Heart Failure with Recovered Ejection Fraction: A Distinct Phenotype
Patients suffering from systolic heart failure who subsequently improve their ejection fraction experience a more favorable clinical course compared to those presenting with persistently reduced ejection fraction or heart failure with preserved ejection fraction.
-
Hypothyroidism and PCI Outcomes
Hypothyroidism is common in patients undergoing percutaneous coronary interventions in a multivariate adjusted observational study was associated with worse long-term outcomes.
-
Optimal Blood Pressure in Patients Presenting with Aortic Stenosis
A post-hoc analysis of patients suffering from mild to moderate aortic stenosis in a study of low-density lipoprotein cholesterol lowering showed that the optimal blood pressure for the best survival was 130-139/70-90 mmHg.
-
An Important Update in the Bare-metal vs. Drug-eluting Stent Debate
This randomized trial showed no difference between contemporary drug-eluting stents and bare-metal stents with regard to death and myocardial infarction, while drug-eluting stents demonstrated an advantage in both repeat revascularization and stent thrombosis at six years of follow-up.
-
Has the Benefit of Prophylactic ICDs Been Overestimated Among Those Suffering From Nonischemic Cardiomyopathy?
Prophylactic implantable cardioverter defibrillator implantation does not provide mortality benefit for nonischemic heart failure patients.